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Summary
 
The 
 
N
 
-propionylated group B meningococcal polysaccharide (NPrGBMP) mimics a unique
protective epitope on the surface of group B meningococci (GBM) and 
 
Escherichia coli
 
 K1. Us-
ing a series of monoclonal antibodies (mAbs) induced by the NPrGBMP–monomeric tetanus
toxoid (TT) conjugate vaccine it was demonstrated that mAbs having specificities for both ex-
tended and conventional short segments of the NPrGBMP were formed, but only the former
were bactericidal, and/or gave passive protection against live challenge by GBM. The failure of
mAbs specific for short epitopes to protect was further established when (NeuPr)
 
4
 
–TT was
used as the vaccine. Of all the mAbs produced that were specific for short internal segments of
the NPrGBMP, none were protective, despite the fact that most of them cross-react with the
GBM capsular polysaccharide. In contrast, most of the protective mAbs produced by NPrGBMP–
TT did not recognize the group B meningococcal polysaccharide (GBMP) unless it was
present in its aggregated high molecular weight form. The bactericidal epitope mimicked by
the NPrGBMP was shown to be ubiquitous in the capsule of both GBM and 
 
E. coli
 
 K1 using
immunogold labeling techniques and, because of its unique properties, its identification could
be significant in the development of a comprehensive conjugate vaccine against group B men-
ingococcal meningitis. This is because most known human 
 
a
 
(2–8)-polysialic acid self-antigens
can be accommodated in 30–50 
 
a
 
(2–8)-linked sialic acid residues, which is roughly equivalent
to an 11-kD length of the GBMP. It has been hypothesized that the formation of the protec-
tive epitope on the surface of GBM is due to the interaction of helical segments of the GBMP
with another molecule and that the protective epitope is mimicked by the NPrGBMP. Sup-
port for the above hypothesis is provided by the fact that the protective NPrGBMP epitope has
a similar unusual length dependency to that of the GBMP epitope.
 
G
 
roup B meningococci (GBM)
 
1
 
 remain a major world
health problem and the poor immunogenicity of the
group B meningococcal polysaccharide (GBMP) prevents
the formulation of a comprehensive polysaccharide-based vac-
cine against meningococcal meningitis (1). While the cova-
lent coupling of the GBMP to protein carriers to form
T-dependent antigens did result in enhanced polysaccha-
ride-specific antibody levels, including antibodies of the
IgG isotype, these levels were still generally low and no
bactericidal activity was reported (2, 3). It is probable that
molecular mimicry is involved in the poor immunogenicity
of the GBMP because its capsule, which is also identical to
that of 
 
Escherichia coli
 
 K1, consists of a homopolymer of
 
a
 
(2–8)-linked sialic acid residues (4), and similar structures
have been identified in human tissue antigens (5, 6). The
sizes of these human tissue antigens range from shorter tri-
meric fragments found in mammalian gangliosides (7) to
well in excess of decameric fragments carried by neural cell
adhesion (N-CAM) glycoproteins and other tissues includ-
ing human tumors (6).
Despite the poor immunogenicity of the GBMP, GBMP-
specific antibodies can be produced in special circumstances
(8, 9) and it has been established that all these antibodies
require a minimum of about nine sialic acid residues for
binding to occur (10, 11). It has been proposed that the above
antibodies recognize an extended helical form of 
 
a
 
(2-8)-poly-
sialic acid on the basis that 
 
a
 
(2-8)-polysialic acid and poly(A),
 
1
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Unique Bactericidal Group B Meningococcal Capsular Epitope
 
with a known propensity to form extended helices, share a
common length-dependent epitope (12). Support for this hy-
pothesis has been obtained by potential energy calculations
and nuclear magnetic resonance spectroscopy (NMR) studies,
which indicate that 
 
a
 
(2-8)-polysialic acid can form local he-
lices of this type (13, 14). More convincing evidence was
obtained by x-ray diffraction analysis of a Fab fragment of
an 
 
a
 
(2–8)-polysialic acid–specific monoclonal IgG antibody
(mAb 735) in which the binding site was shown to be a
groove that could accommodate such an extended helical
structure (15).
Currently, there is no vaccine against group B meningo-
coccal meningitis and most efforts to develop an effective
vaccine have focused on alternative surface-exposed com-
ponents such as outer membrane proteins and lipopolysac-
charides (8). Many problems associated with the develop-
ment of vaccines based on these components have been
identified, not the least of which is their intrinsic antigenic
diversity (8). Because the GBMP is the only conserved an-
tigenic structure on the surface of GBM, a polysaccharide-
based vaccine would be the vaccine of choice, provided
one could overcome its poor immunogenicity without del-
eterious autoimmune effects. A novel approach to achieve
this goal is to replace the 
 
N
 
-acetyl groups of the GBMP
with 
 
N
 
-propionyl groups before its conjugation to tetanus
toxoid (TT) to form a synthetic glycoconjugate vaccine (16).
The NPrGBMP–TT conjugate, when administered in CFA,
was able to induce high titers of NPrGBMP-specific anti-
bodies in mice, which were highly bactericidal for GBM
(16, 17) and passively protective against 
 
E. coli
 
 K1 (17). It
was demonstrated by absorption experiments that the poly-
clonal NPrGBMP-specific antisera consists of two popula-
tions of antibodies, one of which (minor population) cross-
reacts with the high molecular weight (hmw) GBMP but is
not bactericidal, whereas surprisingly the other larger pop-
ulation of hmw GBMP noncross-reactive antibodies con-
tains all the bactericidal activity (18, 19). This evidence in-
dicated that the NPrGBMP mimics a different epitope on
the surface of GBM and 
 
E.coli
 
 K1 than is presented by the
hmw GBMP (18, 19). To define further this epitope, we
have produced a series of mAbs using an NPrGBMP–TT
conjugate as immunogen. Using these mAbs, we have es-
tablished that the NPr GBMP protective epitope has the
same length dependency as the GBMP epitope, and that
the natural epitope it mimics is located in the capsular layer
of both GBM and 
 
E. coli
 
 K1 but can be detected in the
hmw GBMP.
 
Materials and Methods
 
Materials.
 
Colominic acid, sodium salt (
 
E. coli
 
 K1) was ob-
tained from Nacalai Tesque (Kyoto, Japan). Human serum albu-
min (HSA) was obtained from Sigma Chemical Co. (St. Louis, MO),
and TT was obtained from Statenserum Institut (Copenhagen, Den-
mark).  RIBIs complete adjuvant system (RIBI ImmunoChem,
Hamilton, MT) was used according to the specifications of the
manufacturer. 
 
Neisseria meningitidis
 
 strains 80–165 (B:2b:P1. Ham)
and M992 (B:5:P1.1,7), and 
 
E. coli
 
 841743 (018:K1:H7) were
obtained from the culture collection of the Laboratory Centre for
Disease Control (Ottawa, Canada). The hmw GBMP was pre-
pared and purified from strains M992 and 841743 as previously
described (20), except that a GC medium was employed. mAb735
was provided by Professor D. Bitter-Suermann, Medizinische Hoch-
schule (Hannover, Germany). 
 
1
 
H– and 
 
13
 
C–NMR spectra were
recorded at 500 and 125 MHz, respectively with a Bruker AMX
500 instrument in the pulsed Fourier-transform mode at 300
 
8 
 
K.
The polysaccharides and oligosaccharides were twice lyophilized
from 99.7% D
 
2
 
O and were examined in the same solvent.
 
Synthesis of NPr GBMP.
 
NPrGBMP was prepared as previ-
ously described (16) with modifications resulting in improved
yields of product. Colominic acid (500 mg) was 
 
N
 
-deacetylated
using 2M NaOH (10 ml) containing NaBH
 
4
 
 (100 mg) for 6.5 h
at 110
 
8
 
C. The 
 
N
 
-deacetylated polysaccharide was treated directly
with propionic anhydride (10 eq) in small installments while
maintaining the pH at 9.5 with the use of an autotitrator and 2N
NaOH. The solution was then exhaustively dialyzed against
dH
 
2
 
O at 4
 
8
 
C and lyophilyzed. Complete 
 
N
 
-propionylation was
confirmed by integrating appropriate signals in the 
 
1
 
H–NMR
spectrum of the product (16).
 
Synthesis of a 11-kD NPrGBMP–TT.
 
The NPrGBMP was acti-
vated as previously described (16) by selective periodate oxidation
(100 eq/polysaccharide) of the nonreducing terminus, followed
by size fractionation of the polysaccharide on a Bio-Gel A.5 col-
umn (Bio-Rad, Richmond, California). Selection of a 11-kD frag-
ment with a narrow size range (10–12 kD) was accomplished by
screening the resultant fractions using SEC–HPLC (Superose-12,
Pharmacia Biotech, Uppsala, Sweden), and comparing them with
a calibration curve constructed using a series of salic acid (NeuAc)
 
n
 
oligosaccharides. The choice of an 11-kD fragment was based on
the fact that mouse polyclonal antisera induced by this vaccine,
rather than others synthesized using longer or shorter lengths of
NPrGBMP, was optimal in terms of bactericidal activity (data not
shown). The oxidized 11-kD fragment (10 mg), referred to
henceforth as NPrGBMP, was then combined with freshly puri-
fied monomeric (2) TT (3 mg) in a solution of phosphate buffer
(0.2 M; pH 8.1) containing NaBH
 
3
 
CN (6 mg) and incubated at
37
 
8
 
C for 5 d. The material was purified by gel filtration chroma-
tography on Bio-Gel A.5. Sialic acid content was determined by
the method of Svennerholm (21) and protein was determined us-
ing a modified bicinchoninic acid protein microassay (Pierce,
Rockford, IL). The final conjugate was found to contain 30%
sialic acid (wt/wt), which is equivalent to six chains of polysac-
charide per TT molecule. In a similar manner, equivalent 11-kD
fragments NPrGBMP and GBMP were conjugated to HSA for
use as coating antigens.
 
Synthesis of an 
 
a
 
(2–8)-linked (NeuPr)
 
4
 
–TT.
 
The 
 
N
 
-propiony-
lated 
 
a
 
(2–8)-linked sialooligosaccharides (NeuPr)
 
n
 
 were obtained
as previously described (10), except that the partial hydrolysis was
optimized for the production of (NeuPr)
 
10
 
. This was determined
by both anion exchange HPLC (Mono-Q) and SEC–HPLC (Su-
perdex G-75) using appropriate oligosaccharide standards. In
brief, the NPrGBMP (500 mg) was hydrolyzed in NaOAc buffer
(0.2 M; pH 5.1) for 30 min at 70
 
8
 
C, and the oligomers were sep-
arated on a DEAE Sephadex A-25 ion exchange column (Cl-form)
(Pharmacia) using a NaCl gradient elution. The degree of poly-
merization and purity of the oligomers was also confirmed by
 
1
 
H– and 
 
13
 
C–NMR. The purified (NeuPr)
 
4
 
 oligosaccharide (10
mg; 4 mg/ml) was activated using NaIO
 
4
 
 (2 eq) at 4
 
8
 
C for 60
min, and activated (NeuPr)
 
4
 
 was purified on a Sephadex G-10
(Pharmacia) desalting column. Oxidized (NeuPr)
 
4
 
 (2 mg) was
combined with monomeric TT (5 mg; 45:1 molar ratio) in so- 
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dium phosphate buffer (0.33 ml; 0.2 M; pH 8.1) containing
NaBH
 
3
 
CN (7 mg) and heated at 37
 
8
 
C for 5 d. The (NeuPr)
 
4
 
–TT
conjugate was purified on a Bio-Gel A.5 column in PBS buffer
(pH 7.6). The final conjugate contained 4.3% sialic acid or six
chains of (NeuPr)
 
4
 
 per TT molecule. A (NeuPr)
 
4
 
–HSA conjugate
was also synthesized as a coating antigen essentially as described
above for the (NeurPr)
 
4
 
–TT conjugate.
 
Preparation of a (NeurPr)
 
4
 
–HSA Coating Antigen Via Conjugation
of (NeuPr)
 
5
 
 Through the Reducing Terminus ([NeurPr]
 
4RE
 
–HSA).
 
Purified (NeuPr)
 
5
 
 oligosaccharide (9 mg; 5.5 umol) was com-
bined with HSA (5 mg; 0.074 
 
m
 
mol) and NaBH
 
3
 
CN (8.7 mg;
0.14 mmol) and the mixture was dissolved in 250 
 
m
 
l of borate
buffer (0.2 M; pH 9.2). The mixture was heated at 37
 
8
 
C for 5 d
with periodic monitoring by SEC–HPLC (Superose-12; Pharma-
cia). At the end of the 5-d interval, the conjugate was purified by
passage of the mixture over a column of Bio-Gel A.5 (1.6 
 
3
 
 50
cm) equilibrated in PBS. The high molecular weight peak was
collected, dialyzed against dH
 
2
 
O, and lyophilized to 8.7 mg of
(NeuPr)
 
4RE
 
–HSA.
 
Preparation of MAbs.
 
NPrGBMP–TT and (NeuPr)
 
4
 
–TT were
injected intraperitoneally into two groups of five BALB/c mice
(6–8 wk; Charles River, St. Constant, Canada). Each mouse re-
ceived 2 
 
m
 
g of sialic acid in 0.2 ml of RIBIs complete adjuvant
per injection. The mice were boosted with an equivalent amount
of vaccine on day 21, test bled via the tail vein on day 29, and the
mouse with the highest antibody titer to the homologous antigen
was selected for a final intravenous boost on day 35 with the vac-
cine in saline (0.1 ml). 3 d after intravenous boost, the mice were
splenectomized and the spleen cells were fused with Sp
 
2
 
/O my-
eloma cells using a 10:1 ratio of spleen cells to myeloma cells. The
resulting hybridomas were screened by ELISA with a panel of
HSA conjugates and the selected hybridomas were cloned by
limiting dilution. For the production of ascites fluids, pristane
primed BALB/c mice were injected intraperitoneally with 2 
 
3
 
 10
 
6
 
cells in 0.5 ml DMEM and the resulting fluid was collected and
pooled daily. MAbs were purified from ascitic fluid by affinity
chromatography on protein A– or G–Sepharose columns (Phar-
macia). The final concentrations of the purified mAbs were deter-
mined using the modified bicinchoninic acid protein microassay.
 
ELISA for Measuring Direct Binding of mAb.
 
The wells of Corn-
ing microtiter plates (Corning Glass Works, NY) were coated at
37
 
8
 
C for 1 h with various HSA conjugates (1 
 
m
 
g/100 
 
m
 
l PBS/
well) or by the hmw GBMP after a precoating of the wells with
BSA (1 
 
m
 
g/100 
 
m
 
l PBS/well). The plates were then washed
(three times) with PBS and Tween-20 (0.05%) (Allen Fisher Assoc.,
Haddonfield, NJ), followed by blocking with 200 
 
m
 
l of 1% BSA in
PBS for 1 h at room temperature. The contents of the wells were
removed and serial dilutions (100 
 
m
 
l/well) of either culture superna-
tant, ascites, or purified mAb in 3% BSA were performed, followed
by incubation for 60 min at ambient temperature. After washing
(three times, PBS and Tween-20), 100 
 
m
 
l of a 1:2,000 dilution in
3% BSA of a peroxidase-labeled goat anti–mouse IgG(H 
 
1 
 
L) or
IgG 
 
1 
 
IgM antibody (Kirkegaard & Perry Laboratories, Gaithers-
burg, MD) was added and the plates were incubated for 1 h at
room temperature. The wells were then reacted after washing
(three times, PBS and Tween-20; one time, PBS) with 50 
 
m
 
l of
TMB and peroxide substrate (Kirkegaard & Perry Laboratories)
and allowed to develop for 10 min before stopping with 1 M
H
 
3
 
PO
 
4
 
 (50 
 
m
 
l). The plates were read at 450 nm using a BioTek
multiscan ELISA plate reader. Isotyping experiments were per-
formed using an ELISA system as described above with the substitu-
tion of peroxidase-labeled goat anti–mouse isotype-specific anti-
bodies (Southern Biotechnology Associates, Birmingham, AL).
 
Competitive Inhibition ELISA with NeuPr Oligosaccharides.
 
NPrGBMP–HSA or (NeuPr)
 
4
 
RE–HSA was coated on the wells
of a Corning microtiter plate (1 
 
m
 
g/100 
 
m
 
l PBS/well) for 1 h at
37
 
8
 
C. The plate was washed (three times) with PBS/Tween-20
(0.05%) and the wells were blocked with 200 
 
m
 
l of 1% BSA in
PBS for 1 h at 37
 
8
 
C. Concurrently, a second microtiter plate
containing serial twofold dilutions in PBS of NeuPr oligosaccha-
rides (50 
 
m
 
l total vol) was mixed with 50 
 
m
 
l of a previously deter-
mined dilution of mAb in 3% BSA that yielded a OD
 
450
 
 
 
5
 
 1.
This mixture was incubated at 4
 
8
 
C for 1 h and the contents of the
plate were transferred to the original blocked plate with absorbed
NPr antigen. The plate was then incubated at 4
 
8
 
C for 1 h, fol-
lowed by washing (three times) with PBS/Tween-20. A 1:10,000
dilution in 3% BSA of goat anti–mouse IgG(H 
 
1 
 
L) (100 
 
m
 
l/
well) was added to the wells and the plate was incubated at room
temperature for 1 h. The plate was washed (three times) with
PBS/Tween-20, followed by PBS alone. Substrate consisting of
TMB-peroxide was added (50 
 
m
 
l/well) and the plate was allowed
to develop for 10 min, quenched with 50 ml of 1M H3PO4 and
OD measurements at 450 nm were taken.
Bactericidal Assays. The bactericidal assay was carried out in
tissue culture 96-well microtiter plates (Corning). GBM (strain
80–165 B:2b:P.1) was grown overnight on chocolate agar plates
(QueLab, Montreal, Quebec, Canada) at 378C under a 5% CO2
atmosphere, followed by inoculating a second plate and incubat-
ing it for 5 h. Appropriate dilutions of culture supernatent or of
the purified mAb were made directly in the plate using HBSS
containing 1% casein hydrolyzate, diluted to a final volume of 50
ml/well. A suspension of GBM in HBSS, 1% casein hydrolyzate
was made giving an OD490 5 0.29 and a final working dilution of
bacteria was prepared by a further 1:20,000 dilution. Freshly
thawed baby rabbit complement was added (20 ml) to each well,
followed by 30 ml of the working dilution of bacteria (2,500
CFU/well). The plate was then shaken at 378C for 1 h. The con-
tents of each well was then mixed before plating (10 ml) on to
chocolate agar. The agar plates were incubated overnight at 378C,
5% CO2 and the number of CFU were counted. The percent of
killing was calculated relative to the mean values of either HBSS
control wells or culture supernatant medium in the following
manner: percentage of killing 5 (CFUcontrol 2 CFUmAb / CFUcontrol)
3 100.
Passive Protection Experiments. Groups of five female CF1 mice
(8–10 wk; Charles River, St. Constant, Quebec, Canada) were in-
jected intravenously with 200 ml of known concentrations of pu-
rified mAbs in sterile PBS. After 1 h, each group of mice was
challenged with an intraperitoneal injection (500 ml) containing
800–1,200 CFU of GBM (80–165) per ml of brain heart infu-
sion/PBS. After 5 h, the blood was harvested from the individual
mice by cardiac puncture, and 10 ml of blood was plated onto
chocolate agar plates. The plates were incubated at 378C under
5% CO2 and the number of CFUs were determined 15–20 h
later. The percent of clearance of bacteria was calculated relative
to control mice receiving either an irrelevant antiserum or PBS as
follows: percent of clearance 5 (CFUcontrol 2 CFUmAb / CFUcontrol)
3 100.
Electron Microscopy. GBM (M992) and E. coli K1 (841743)
were grown on Columbia broth plates (QueLabs) and suspensions
of the bacteria in Hepes buffer (Research Organics, Inc., Cleve-
land, OH), 0.1 M, pH 6.8, were prepared. Nickel 200 mesh grids
coated with Formvar and carbon were floated on 100 ml droplets
for 30 s. Excess liquid was blotted off, and then the grids pro-
cessed for immunolabeling as previously described (22). Then the
grids were subjected to the following sequential procedures. They1932 Unique Bactericidal Group B Meningococcal Capsular Epitope
were blocked with BSA in 1% PBS for 30 min before incubation
with either mAb 735, 6B9, or 13D9. The grids were then re-
blocked (three times for 3 min) with 1% BSA in PBS. The grids
were then reacted for 1 h with a protein A gold solution (Sigma)
diluted 1:50. They were then washed with PBS (three times for 3
min) and finally with ultrapure water. The grids were then
viewed in a Philips EM300, operating at 60 kV with the liquid
nitrogen cold trap in place.
Results
Preparation and Screening of mAbs. For screening mAbs
produced by the NPrGBMP–TT, an NPrGBMP–HSA
conjugate having the same length as NPrGBMP was em-
ployed. 69 hybridomas induced by NPrGBMP–TT were
identified and subcloned. In earlier studies (18) using a sim-
ilar NPrGBMP–TT vaccine to induce polyclonal antisera
in mice, the presence of antibodies specific to extended
segments of NPrGBMP was detected. This phenomenon is
associated with immune responses to the GBMP (10, 11)
and has been attributed to immune selection where only
antibody responses to extended helical segments of the
GBMP have been reported (11). Antibody responses to
shorter segments of the NPrGBMP were not looked for in
previous polyclonal studies, but by screening the panel of
hybridomas with (NeuPr)4–HSA, a single clone (6B9) with
a specificity for a conventional shorter epitope was de-
tected. Owing to the paucity of mAbs with a specificity for
shorter epitopes, a second series of hybridomas were gener-
ated using a vaccine synthesized with (NeuPr)4. Thus, it
was anticipated that (NeuPr)4–TT would force an antibody
response to shorter segments of the NPrGBMP. mAbs hav-
ing a specificity for short segments of the NPrGBMP may
be directed towards either terminal or internal residues of
the polymer, therefore, because our interest was focused on
the latter, the following screening strategy was employed.
In addition to (NeuPr)4–HSA, where (NeuPr)4 was linked
directly through its nonreducing end, (NeuPr)4RE–HSA
was synthesized in such a way as to link (NeuPr)4 to HSA
through the opposite end. To accomplish this, (NeuPr)5
was linked directly to HSA through its reducing end to HSA
by reductive amination, thus transforming its terminal reduc-
ing NeuPr residue into an open chain spacer. The structures
Figure 1. Structures of the
(NeuPr)4 screening antigens
linked  through the nonreducing
end ([NeuPr]4–HSA) (top), and
through the reducing end
([NeuPr]4RE–HSA) (bottom).
Table 1. Initial Screening of Immunological Properties of mAbs 
Produced by (NeuPr)4–TT and NPrGBMP–TT
Characteristic (NeuPr)4–TT NPrGBMP–TT
Isotype IgG1 13/56 24/42
IgG2a 16/56 10/42
IgG2b 23/56 1/42
IgG3 4/56 7/42
Antigenic
specificity NPrGBMP 8/8 29/29
(NeuPr)4 8/8 1/29
(NeuPr)4RE 8/8 1/29
GBMP 7/8 2/29
Bactericidal
activity IgG1 0/3 0/22
IgG2a 0/6 6/8
IgG2b 0/14 1/1
IgG3 0/3 7/71933 Pon et al.
Table 2. Immunological Properties of Selected mAbs Induced by (NeuPr)4–TT and NPrGBMP–TT
Vaccine Clone Isotype
Antigenic Specificity*
Epitope
size
Bactericidal
activity
Passive
protection NPrGBMP (NeuPr)4 (NeuPr)4RE GBMP mw GBMP
(NeuPr)4–TT 10B9 IgG1 1* 11 11 Short NB 0%
7C11 IgG1 111 11 Short NB 0%
11G1 IgG2a 111 11 Short NB 0%
1F1 IgG2b 111 11 Short  NB 20% @ 50 mg
11F3 IgG3 111 11 Short NB 11% @ 50 mg
NPrGBMP–TT 13A8 IgG1 12 ‡ 22 1 Extended NB 97% @ 100 mg
76% @ 50 mg
56% @ 2 mg
6E10 IgG1 122 22 Extended NB 40% @ 50 mg
13A11 IgG1 122 2 § 1 Extended NB 90% @ 50 mg
13D9 IgG2a 122 21 iExtended 1.2 mg/ml 99% @ 100 mg
92% @ 10 mg
79% @ 2 mg
6B9 IgG2a 111 22 Short NB 0% @ 50 mg
12C5 IgG2b 122 21 Extended 23 mg/ml 87% @ 100 mg
82% @ 50 mg
12E12 IgG3 122 21 Extended 14 mg/ml —
14F10 IgG3 122 2 § 1 Extended 1.2 mg/ml 98% @ 100 mg
GBM 735¶ IgG2a 122 11 Extended 2.0 mg/ml —
*All positive values were a minimum of 50% of the binding of NPrGBMP.
‡Less than 0.10 D.
§Cross-reactions less than 8% of response to NPrGBMP.
iReacts with hmw GBMP from E. coli K1.
¶See references 9 and 15.
selected from the initial screening of clones, ensuring that
all isotypes were represented. The antigenic specificity of
these mAbs was determined using a direct binding ELISA
with NPrGBMP–HSA, (NeuPr)4–HSA, and (NeuPr)4RE–
HSA coating antigens. In addition, a GBMP–HSA coating
antigen was used in the assay to identify any mAbs that
cross-reacted with the GBMP. The results of these experi-
ments are shown in Table 1. Those mAbs deemed to be
specific for an antigen were characterized by at least 100-
fold greater titer towards the homologous antigen relative
to other antigens. All eight mAbs produced by (NeuPr)4–
TT reacted equally well with (NeuPr)4–HSA, (NeuPr)4RE–
HSA, and NPrGMBP–HSA, thus indicating that the short
epitopes expressed on (NeuPr)4 were probably present in in-
ternal segments of NPrGBMP. In addition, seven of eight
of the above mAbs cross-reacted with GBMP–HSA to the
extent of >90% of the reaction with the homologous anti-
gen, only one of the eight being specific for NPrGBMP–
HSA. Of the twenty-nine mAbs produced by NPrGBMP–
TT, all reacted with the homologous NPrGBMP–HSA,
but only one of them reacted with (NeuPr)4–HSA. This
mAb (6B9) also reacted equally well with (NeuPr)4RE, and
thus probably originated from an epitope situated on an in-
of the screening antigens are shown in Fig. 1, and because they
differ in structure at both ends, it was rationalized that any
mAbs reacting with both screening antigens would probably
be specific for internal segments of the NPrGBMP. Using
the above strategy, 75 hybridomas induced by (NeuPr)4–
TT were identified and subcloned.
Distribution of Isotypes. Isotyping 56 clones produced by
(NeuPr)4–TT and 42 clones produced by NPrGBMP–TT
was carried out to assess both the clonality of the positive
hybridomas as well as to aid in the selection of clones for
more extensive studies. The breakdown of the distribution
of isotypes raised to both immunogens is given in Table 1.
56 clones stemming from the (NeuPr)4–TT fusion were
screened, leading to a relatively even distribution of IgG1-
(23%), IgG2a (29%), and IgG2b (41%) antibody isotypes
with relatively few IgG3 (7%) secreting clones identified.
The isotype distribution found among 42 clones obtained
from the NPrGBMP–TT fusion differed significantly, with
a bias toward IgG1 secreting clones (57%), followed by ap-
proximately equal amounts of IgG2a (24%) and IgG3
(17%), with only one IgG2b secreting clone identified.
Antigenic Specificity of mAbs. 8 mAbs from the (NeuPr)4–
TT fusion and 29 from the NPrGBMP–TT fusion were1934 Unique Bactericidal Group B Meningococcal Capsular Epitope
ternal segment of the NPrGBMP rather than on its termi-
nus. In contrast with the mAbs produced by (NeuPr)4–TT,
those produced by NPrGBMP–TT were much less cross-
reactive with GBMP–HSA. Only 2 of 29 mAbs tested
were cross-reactive, the degree of cross-reactivity being
much less (,8%). From the mAbs, listed in Table 1, five
produced by (NeuPr)4–TT and eight produced by NPr-
GBMP-TT were selected for further studies. They were se-
lected to ensure a comprehensive rather than a statistical
representation of isotypes and antigenic specificities. The
individual antigenic specificities of the selected mAbs are
shown in Table 2, together with data obtained using the
hmw GBMP as an additional screening antigen. On the ba-
sis of the introduction of this latter antigen to the screening
process a clear differentiation in the antigenic specificities
of mAbs produced by NPrGBMP–TT and (NeuPr)4–TT
could be made. While all of the mAbs produced by the
former vaccine, with the exception of one (6B9), reacted
exclusively with the hmw GBMP, those produced by the
latter vaccine reacted equally well with both the GBMP and
the hmw GBMP.
Antigenic specificity of mAbs based on the use of screen-
ing antigens does not provide precise information on the
epitope size and, therefore, to achieve this, each of the in-
dividual mAbs listed in Table 2 was subjected to competi-
tive ELISA experiments similar to those previously de-
scribed (19). When oligomers of increasing size were used
to inhibit the binding of mAbs produced by NPrGBMP–
TT to NPrGBMP–HSA, all the mAbs except one (6B9) gave
similar inhibition curves. The inhibition curves of 13D9,
typical of the majority of the mAbs, together with 6B9 are
shown in Fig. 2. With the majority of mAbs, the inhibitory
properties of the oligomers maximized at (NeuPr)14–16 and
the epitopes were thus designated as extended in Table 2.
In contrast, when oligomers of increasing size were used to
inhibit the binding of 6B9 to NPrGBMP–HSA the inhibi-
tion maximized at (NeuPr)5, and the epitope was defined as
short in Table 2. All the mAbs produced by (NeuPr)4–TT
gave similar inhibition profiles to 6B9, except that as ex-
pected, based on the fact that the vaccine is composed of
only four NeuPr residues, the inhibitory properties of the
oligomers maximized at (NeuPr)4.
Bactericidal Activity of mAbs. From an initial qualitative
bactericidal screening (Table 1), purified mAbs selected for
more rigorous characterization were subjected to quantita-
tive bactericidal assays and the results of these assays are
listed in Table 2. The assays were carried out using a modi-
fication of a published procedure (18) in which significantly
more organisms (2,500 CFU) per test were used, resulting
in a shift towards the detection of mAbs with the strongest
bactericidal activity. From an analysis of the bactericidal re-
sults listed in Table 2, one can reach the definite conclusion
that there is a strong correlation between mAbs that recog-
nize an extended epitope and their ability to kill GBM by
bacteriolysis. The only exceptions to the rule are mAbs
13A8, 6E10, and 13A11, which can only be differentiated
from the mAbs above by the fact that they are all of the
IgG1 isotype. There is evidence that mouse antibodies of
this isotype are less able to fix complement and this is am-
ply confirmed from an initial screen of bactericidal activity
of 38 mAbs produced by NPrGBMP–TT in which none
of 22 mAbs of the 1gG1 isotype that were detected were
bactericidal (Table 1). The other observation of interest is
that none of the mAbs, regardless of isotype, which recog-
nise a short epitope, whether induced by either (NeuPr)4–
TT or NPrGBMP–TT, demonstrated any bactericidal ac-
tivity against GBM in this assay (Table 2).
Passive Protection Induced by mAbs. Purified mAbs were
assayed for their ability to clear GBM-infected mice upon
their passive transfer. The results are expressed as percent
reduction in GBM brought about by a known amount of
purified mAb and they are listed in Table 2. All of the
mAbs that recognize a short epitope, whether induced by
either (NeuPr)4–TT or by NPrGBMP–TT, were not able
to clear the GBM effectively from infected mice. As ex-
pected, strongly bactericidal mAbs, all of which recognize
extended epitopes, were effective in clearing GBM from
infected mice. In addition, all mAbs of the nonbactericidal
IgG1 isotype that recognize an extended epitope were also
able to clear GBM from infected mice, although for mAb
6E10 clearance was the least effective. To determine the
relative effectiveness of bactericidal mAb 13D9 to clear GBM
from infected mice as compared with nonbactericidal mAb
Figure 2. ELISA inhibition of the binding of NPrGBMP–HSA to
mAb 6B9 (top) and mAb 13D9 (bottom) using a series of a(2–8)-linked
homooligosaccharides (NeuPr)n.1935 Pon et al.
13A8, their ability to clear GBM with reducing quantities
of mAbs was investigated. The results shown in Table 2 in-
dicate that the effectiveness of the nonbactericidal mAb
13A8 to clear GBM was reduced much faster than that of
the bactericidal mAb 13D9.
Surface Expression of Extended NPrGBMP-specific Epitopes.
Immunogold labeling experiments were carried out with
mAbs 735, 13D9, and 6B9 on both GBM and E. coli K1
and the results are shown in Fig. 3. E. coli K1 was included
in the experiment because it has the same a(2–8)-polysialic
acid capsule as GBM. 13D9 and 6B9 were chosen because
both were produced using the same NPrGBMP–TT vac-
cine and both do not recognize GBMP. In addition, they
are both of the same isotype (IgG2a). They differ in the fact
Figure 3. Immunogold labeling of Escherichia coli K1 using mAbs 735 (A), 13D9 (B), and 6B9 (C), and of group B Neisseria meningitidis using mAbs 735
(D), 13D9 (E), and 6B9 (F).1936 Unique Bactericidal Group B Meningococcal Capsular Epitope
that while 13D9 recognizes an extended epitope on NPr-
GBMP, 6B9 recognizes a short epitope on the same poly-
mer. For a positive control mAb 735 was used, the specific-
ity of which is known to be for an extended helical epitope
of 10 contiguous sialic units in the GBMP (15). A uniform
distribution of mAb 735 was detected on the surface of E.
coli K1 and GBM (Fig. 3, A and D), thus indicating the
presence of the extended helical epitope of the GBMP on
the surface of both organisms. A similar result was obtained
using mAb 13D9, although the density of gold labeling was
reduced for both E. coli K1 and GBM (Fig. 3, B and E)
when compared with that obtained with mAb 735. No
mAb 6B9 was detected on either E. coli K1 or GBM (Fig.
3, C and F).
Discussion
Because the GBMP is the most conserved antigenic
structure on GBM, a polysaccharide-based vaccine would
be the vaccine of choice provided one could overcome its
poor immunogenicity (8). In addition, one would also have
to consider that the antibody generated would not lead to
pathological consequences because the lack of immunoge-
nicity is attributed to structural mimicry between the GBMP
and human tissue antigens (6, 7). One way to achieve this
goal is to use a synthetic vaccine composed of the N-propi-
onylated (NPr) form of the GBMP, which when conju-
gated to TT, induces in mice high titer antibodies that are
bactericidal for all GBM (16, 17). Based on previous evi-
dence that the hmw GBMP failed to absorb out the bacte-
ricidal activity from the above polyclonal antisera it was
concluded that NPrGBMP–TT produced two distinct popu-
lations of antibodies, only one of which was associated with
the hmw GBMP, while the other was associated with a
unique bactericidal epitope on the surface of GBM (18).
Using a series of mAbs induced by NPrGBMP–TT, we
were able to examine mAbs having a variety of individual
immune properties. Although our results are still consistent
with the original hypothesis of the presence of two distinct
epitopes on the surface of GBM, the nature of the bacteri-
cidal epitope needs to be redefined due to the fact that we
were able to detect both epitopes on the hmw GBMP in a
direct binding assay.
One interesting finding that emerges from our data is
that while most of the mAbs induced by NPrGBMP–TT
recognize an epitope located only on extended segments of
the NPrGBMP ([NeuPr]14–15 residues by inhibition), one
was able to bind to shorter internal regions ([NeuPr]4–5 res-
idues by inhibition) of the NPrGBMP. Thus, in contrast
with GBMP-specific antibodies, which up to now have been
shown only to recognize extended helical epitopes (13,
15), NPrGBMP-specific antibodies that recognize both ex-
tended epitopes and conventional short epitopes can be de-
tected. It is not unreasonable to suppose that these epitopes
could have their origins in the internal extended helical and
random coil forms of an intrinsically flexible NPrGBMP (8,
13). NMR studies and potential energy calculations dem-
onstrate that the NPrGBMP can form extended helices,
similar to those identified in the GBMP (14), but so far we
have no X-ray data, as in the case of the GBMP, to support
this hypothesis. However, some supporting serological evi-
dence is available, because mAb735 that recognizes an ex-
tended helical form of the GBMP (15) also cross-reacts
strongly with NPrGBMP (Table 2), as has been demon-
strated previously (11). Comparison of the epitope size with
protective properties of the mAbs also provides another
important observation, because only mAbs that bind to ex-
tended NPrGBMP epitopes were protective against GBM
as defined by bactericidal activity and passive protection
studies. This was also true for mAbs of the IgG1 isotype,
which while not bactericidal, were still able to passively
protect mice against challenge with live GBM, provided
the mAb bound to extended NPrGBMP epitopes.
Because of the paucity of mAbs induced by NPrGBMP–
TT that bound to short epitopes, and our need to evaluate
more of them, additional mAbs were made using (NeuPr)4–
TT. These mAbs were screened to try to eliminate any that
might be specific for terminal segments of the NPrGBMP.
Interestingly, none of these mAbs were bactericidal for, or
had any significant ability to protect passively against, live
GBM even though all of them cross-reacted extensively
with both the GBMP and the hmw GBMP. We have no
explanation for this, but this evidence strongly supports our
original observation that only mAbs with a specificity for an
extended NPrGBMP epitope are protective against GBM.
Another important conclusion that can be reached from
the (NeuPr)4–TT data is that vaccines based on short seg-
ments of the NPrGBMP would be completely inappropri-
ate for human use, both from the point of view of efficacy
and the fact that they also produce antibodies that are highly
cross-reactive with the GBMP. However, it is important to
note that the implications of this cross-reaction, if any, are
not known at this time. Contrary to mAbs induced by
(NeuPr)4–TT, those induced by NPrGBMP–TT reacted
almost exclusively with the hmw GBMP and not with the
GBMP. The exceptions are mAb 6B9, the specificity of
which is exclusive for short segments of NPrGBMP, and
mAbs 13A11 and 14F10, which also cross-react to a limited
extent with the GBMP, presumably through a shared ex-
tended epitope. Thus, all the mAbs in Table 2 can be clas-
sified into two major epitopic specificities based on their
cross-reactions with GBMP and the hmw GBMP.
The presence of these two different epitopes in the cap-
sular layer of GBM and E. coli K1 was confirmed by visual-
ization of the binding of selected mAbs to these bacteria us-
ing an immunogold-labeling technique. mAb 735, which is
known to bind to an extended helical segment of the
GBMP having a minimum of 10 NeuAc residues (15), was
detected in the capsular layer of both GBM and E. coli K1.
However, mAb 735 also cross-reacts with NPrGBMP and
probably binds to both epitopes. Bactericidal mAb 13D9,
which bound to an extended NPrGBMP epitope, but did
not bind to GBMP, was also detected on both GBM and
E. coli K1. However, the labeling was less dense than that1937 Pon et al.
produced by mAb 735, which probably reflects the unique
specificity of mAb 13D9, which binds only to the bacteri-
cidal epitope mimicked by NPrGBMP, and not to GBMP
alone. MAb 6B9, which was of the same isotype as 13D9
but was specific for conventional short NPrGBMP epitopes,
did not bind to either organism, which provides an expla-
nation for its lack of bactericidal activity.
Based on the close structural resemblance between the
NPrGBMP and the GBMP, it has been suggested that the bac-
tericidal epitope on GBM is closely associated with the GBMP
(8, 19). Additional evidence presented in this paper, such as
the length dependency of NPrGBMP epitope, is consistent
with this hypothesis. However, this hypothesis is not con-
sistent with a previous finding in which it was observed
that although GBM and E. coli K1 were able to absorb out
the bactericidal activity from a polyclonal mouse anti-
NPrGBMP–TT serum (19) the hmw GBMP was not (18).
Interestingly, in recent immunization studies in nonhuman
primates, the bactericidal activity induced by an NPrGBMP–
rPorB conjugate could be inhibited by the hmw GBMP
obtained from E. coli K1, although it was much less effi-
cient as an inhibitor than 10-kD NPrGBMP (23). Perhaps
the above anomalies are indicative of the relative instability
of the bactericidal epitope, which while seemingly abun-
dant on the surface of GBM and E. coli K1 (Fig. 3, B and
E) is less so in the isolated hmw GBMP. This instability
could conceivably be attributed to the extraction and puri-
fication procedures used to prepare the hmw GBMP.
The identification of the bactericidal epitope on the hmw
GBMP and the fact that it cannot be expressed on an 11-kD
length of the GBMP indicates that it is only expressed on
the aggregated form of the GBMP (24). It has been pro-
posed that NPrGBMP mimics a complex intermolecular
epitope on the surface of GBM that involves the close asso-
ciation of extended helical portions of the GBMP with an-
other molecule (19). It is tempting to propose that this
other molecule is the phosphoglycerolipid component of
the hmw GBMP, which is situated at the terminus of indi-
vidual short a(2–8)-polysialic chains equivalent to the GBMP,
and causes the chains to aggregate (24). Thus, the bacteri-
cidal epitope could involve either direct participation of the
lipid component or indirect participation, where by gener-
ating the GBMP aggregates, it also stabilizes other complex,
possibly conformational, epitopes. Certainly, it has been
demonstrated that bactericidal NPrGBMP-specific anti-
bodies can be absorbed by short chains of a(2–8)-polysialic
acid provided they are linked to long spacers on a solid sur-
face (19). In conclusion, the evidence above clearly defines
two capsular epitopes, one based on the GBMP and the
other on the hmw GBMP. Should this latter epitope be
unique to the surface of GBM and E. coli K1, it would be
of great significance to the development of a vaccine
against group B meningitis. This is because current studies
indicate that most mammalian a(2–8)-polysialic antigens
are of z50 NeuAc residues or less (6) and could be easily
accomodated in the GBMP. That the hmw GBMP epitope
is unique to the bacteria is supported by the fact that
NPrGBMP–TT readily induces in mice large quantities of
mAbs with a specificity for the hmw GBMP, whereas the
number that cross-react to any extent with the GBMP is
minimal.
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